Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) Short Interest Down 17.0% in March

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) was the recipient of a large decrease in short interest in March. As of March 15th, there was short interest totalling 5,030,000 shares, a decrease of 17.0% from the February 28th total of 6,060,000 shares. Based on an average daily trading volume, of 555,900 shares, the days-to-cover ratio is currently 9.0 days. Approximately 10.0% of the shares of the company are sold short.

Wall Street Analyst Weigh In

Several research firms recently weighed in on SUPN. Cantor Fitzgerald reaffirmed a “neutral” rating and set a $36.00 price objective on shares of Supernus Pharmaceuticals in a research report on Wednesday, February 26th. StockNews.com lowered shares of Supernus Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Monday, March 24th.

Insider Buying and Selling at Supernus Pharmaceuticals

In other news, VP Padmanabh P. Bhatt sold 9,477 shares of Supernus Pharmaceuticals stock in a transaction that occurred on Tuesday, February 4th. The shares were sold at an average price of $39.70, for a total value of $376,236.90. Following the completion of the sale, the vice president now directly owns 10,149 shares in the company, valued at approximately $402,915.30. The trade was a 48.29 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Jonathan Rubin sold 927 shares of the business’s stock in a transaction that occurred on Friday, February 21st. The shares were sold at an average price of $39.15, for a total value of $36,292.05. Following the completion of the sale, the senior vice president now owns 7,853 shares of the company’s stock, valued at approximately $307,444.95. This trade represents a 10.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 11,104 shares of company stock valued at $440,263 in the last ninety days. 9.30% of the stock is currently owned by corporate insiders.

Hedge Funds Weigh In On Supernus Pharmaceuticals

A number of hedge funds have recently bought and sold shares of SUPN. Raiffeisen Bank International AG acquired a new stake in Supernus Pharmaceuticals during the 4th quarter worth about $25,000. GF Fund Management CO. LTD. bought a new stake in Supernus Pharmaceuticals in the fourth quarter valued at $42,000. Smartleaf Asset Management LLC raised its stake in Supernus Pharmaceuticals by 219.1% during the 4th quarter. Smartleaf Asset Management LLC now owns 1,267 shares of the specialty pharmaceutical company’s stock worth $47,000 after buying an additional 870 shares during the period. Mark Sheptoff Financial Planning LLC acquired a new position in shares of Supernus Pharmaceuticals during the fourth quarter worth approximately $52,000. Finally, Headlands Technologies LLC raised its holdings in Supernus Pharmaceuticals by 203.0% during the fourth quarter. Headlands Technologies LLC now owns 1,515 shares of the specialty pharmaceutical company’s stock worth $55,000 after buying an additional 1,015 shares during the last quarter.

Supernus Pharmaceuticals Price Performance

Shares of SUPN stock opened at $32.38 on Tuesday. The stock has a market capitalization of $1.81 billion, a PE ratio of 30.28 and a beta of 0.83. The business’s 50 day simple moving average is $35.05 and its 200 day simple moving average is $35.06. Supernus Pharmaceuticals has a one year low of $25.53 and a one year high of $40.28.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.